Stay updated on Pembrolizumab in Solid/Micropapillary Lung Adeno Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab in Solid/Micropapillary Lung Adeno Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab in Solid/Micropapillary Lung Adeno Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a recent update in the dosage of Pembrolizumab from 7 to 8 mg every 3 weeks for patients with solid or micropapillary lung adenocarcinoma with pathologic stage I and primary tumor no more than 4 cm.
    Difference
    0.1%
    Check dated 2024-06-06T14:29:27.000Z thumbnail image
  4. Check
    6 days ago
    No Change Detected
  5. Check
    7 days ago
    No Change Detected
  6. Check
    17 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to include detailed eligibility criteria for primary lung adenocarcinoma patients, specifying tumor characteristics and health conditions required for study participation. Previously, no information was provided in this section.
    Difference
    54%
    Check dated 2024-05-22T21:14:37.000Z thumbnail image
  7. Check
    39 days ago
    Change Detected
    Difference
    0.8%
    Check dated 2024-04-30T21:54:44.000Z thumbnail image

Stay in the know with updates to Pembrolizumab in Solid/Micropapillary Lung Adeno Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in Solid/Micropapillary Lung Adeno Clinical Trial page.